Answers are grounded in this paper and cite their sources.
These findings establish SIRPabodies as a promising approach to deliver the therapeutic benefit of CD47-SIRPα blockade specifically toward tumor cells. SIRPabodies may be applied to additional cancer types by grafting SIRPα onto other tumor-specific therapeutic antibodies. Clin Cancer Res; 22(20); 5109-19.
No takes yet. Share an insight, caveat, or question.
Piccione et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: